Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update in Kaposi sarcoma.

Ariela Noy1

  • 1Department of Lymphoma and Clinical Immunology, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA. noya@mskcc.org

Current Opinion in Oncology
|September 10, 2003
PubMed
Summary

Recent advances in Kaposi sarcoma pathophysiology, including viral factors like HHV-8 and HIV, are shaping new therapeutic strategies. This review covers the latest developments and their potential impact on other diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Blood advances·2026
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Blood cancer journal·2026
Same author

Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I Study.

Cancers·2026
Same author

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Cancers·2026

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Kaposi sarcoma (KS) pathophysiology knowledge is evolving.
  • Therapeutic strategies for KS are influenced by ongoing research.
  • This review focuses on recent advancements within the last 18-24 months.

Purpose of the Study:

  • To summarize recent developments in Kaposi sarcoma pathophysiology.
  • To highlight how these advances influence current and future therapeutic approaches.
  • To provide an overview of emerging treatment strategies.

Main Methods:

  • Literature review of studies published in the last 18-24 months.
  • Synthesis of information on viral factors (HHV-8, HIV), endothelial cells, and host immune factors.
  • Analysis of recent findings related to highly active antiretroviral therapy (HAART).

Related Experiment Videos

Main Results:

  • Key insights into the roles of human herpes virus 8 (HHV-8) and human immunodeficiency virus (HIV) in KS development.
  • Understanding of endothelial cell involvement and host immune responses, including cytokine influences.
  • Review of current therapeutic agents and those under investigation, informed by pathophysiological understanding.

Conclusions:

  • Advances in understanding Kaposi sarcoma pathophysiology are directly leading to novel therapeutic approaches.
  • These new strategies hold promise for improving KS treatment outcomes.
  • The impact of these findings may extend to other viral and malignant conditions.